Shiitake vs. Maitake for Cholesterol: The Research Verdict

Mushrooms & Cardiovascular Health

10x eritadenine variation

Eritadenine content varies up to 10-fold across different shiitake strains, making supplement quality critical. Maitake lacks eritadenine entirely; its cardiovascular benefits come through a different pathway.

Enman et al., Journal of Agricultural and Food Chemistry, 2007

66 days

duration of the only double-blind shiitake cholesterol RCT, which confirmed significant triglyceride reduction (Spim 2021)

Eritadenine

shiitake's unique compound: inhibits SAH hydrolase, promoting bile acid conversion; absent in maitake and most other mushrooms

Blood pressure

maitake's primary cardiovascular strength per the research: insulin sensitization and antihypertensive effects, not direct cholesterol lowering

Enman et al., Journal of Agricultural and Food Chemistry, 2007

View as image ↗

Most content comparing shiitake and maitake for cholesterol treats them as interchangeable. They are not. These two mushrooms have different bioactive compounds, different mechanisms of action, and different evidence profiles for lipid management.

Shiitake contains eritadenine, a compound found in few other food sources, which operates through a biochemical pathway distinct from all the other cholesterol-lowering compounds in mushrooms. Maitake does not contain eritadenine. Maitake's cardiovascular research points toward blood pressure regulation and insulin sensitization rather than direct cholesterol lowering.

This article presents what each mushroom's evidence base actually shows, where they differ, and which one the limited human clinical trial data supports for lipid management specifically.

For the broader mushroom cholesterol landscape including oyster and reishi, see Mushrooms That Lower Cholesterol: What the Research Shows.

Eritadenine: The Compound That Makes Shiitake Biochemically Different

Among the many bioactive compounds studied for cholesterol effects, eritadenine is unusual. It is found in very few food sources, with shiitake mushroom (Lentinus edodes) being its primary known dietary source. Its mechanism of action is also distinct from the other pathways by which mushrooms affect cholesterol.

Two separate lines of research define eritadenine. Enman and colleagues (2007) developed a reliable HPLC method to quantify eritadenine across four shiitake strains,^[2] and Yamada and colleagues (2007) characterized how it lowers cholesterol at the enzyme level.^[10] The key findings:

1. Eritadenine is a potent inhibitor of S-adenosyl-L-homocysteine (SAH) hydrolase, an enzyme involved in methylation reactions and the metabolism of homocysteine (Yamada et al., 2007).

2. This inhibition, through a cascade of metabolic effects including altered hepatic phospholipid metabolism, promotes conversion of cholesterol to bile acids in the liver, reducing serum cholesterol.

3. Eritadenine content varies widely by strain. The strains Enman and colleagues characterized contained up to 10 times more eritadenine than levels previously reported for other shiitake strains, so an uncharacterized mushroom may contain far less than a selected high-eritadenine strain (Enman et al., 2007).

The 10-fold strain variation is practically important. A shiitake supplement or fresh mushroom from an uncharacterized strain may contain almost no eritadenine, while another from a specifically selected high-eritadenine strain would contain meaningful amounts. This is not a problem most cholesterol-focused mushroom articles acknowledge.

Gil-Ramirez and colleagues (2018) reviewed the molecular actions of hypocholesterolaemic compounds across edible mushrooms, situating eritadenine among them: it is the major cholesterol-lowering compound in edible mushrooms that works through SAH hydrolase inhibition rather than through beta-glucan bile acid binding or HMG-CoA inhibition.^[7] This mechanistic uniqueness makes shiitake worth studying separately from other species.

What the Only Shiitake Double-Blind RCT Actually Found

The most rigorous published shiitake cholesterol study is a 66-day double-blind randomized clinical trial by Spim and colleagues (2021), conducted in adults with borderline high cholesterol.^[1]

Sixty-eight individuals with borderline high cholesterol, LDL, or triglycerides were randomized to placebo (n=32) or a shiitake-bar intervention (n=36), with blood drawn at 0, 33, and 66 days. Results: the intervention group showed a statistically significant ~10% reduction in triglycerides (P=0.0352), raised the endogenous antioxidant reduced glutathione, and lowered lipid peroxidation. LDL-specific reduction was not significant.

This matches a consistent pattern across the mushroom cholesterol literature: triglyceride reduction tends to be more reliable than LDL reduction. The Uffelman 2023 systematic review of 22 mushroom studies across multiple species found the same pattern, with mushrooms consistently improving triglycerides but showing inconsistent effects on LDL.^[8]

One safety finding from the Spim 2021 trial that most competitor articles do not mention: the trial reported dermatitis in 10% of participants sensitive to the mushroom. This is consistent with flagellate dermatitis, a skin reaction characterized by linear scratch-like marks, documented in people who consume large amounts of raw or undercooked shiitake. The culprit is lentinan, a polysaccharide in shiitake that can cause an immune-mediated skin reaction when consumed in large quantities or in incompletely heat-denatured form. Properly cooked shiitake at normal culinary amounts does not typically cause this reaction.

Maitake's Cardiovascular Strength Is Not Cholesterol

Maitake (Grifola frondosa) is often grouped with shiitake in discussions of cholesterol-lowering mushrooms. The evidence profile for maitake is different, and it is worth understanding where maitake's cardiovascular evidence is actually strongest.

Talpur and colleagues (2002) reviewed maitake's metabolic and antihypertensive effects in an animal model study.^[4] The primary finding: maitake produced blood pressure reduction and metabolic improvement, with the mechanism appearing to be primarily insulin sensitization and antihypertensive action. Direct cholesterol lowering was a secondary, less consistent finding.

Kundakovic and colleagues (2013) reviewed multiple species for metabolic syndrome management and reached a similar conclusion about maitake: its contribution to metabolic health is primarily through insulin sensitization and blood pressure effects, with shiitake's eritadenine more uniquely relevant for cholesterol specifically.^[5]

The foundational comparative animal study (Kabir et al., 1987) is frequently cited to support both shiitake and maitake for cholesterol: in spontaneously hypertensive rats, both mushrooms lowered blood pressure and improved plasma cholesterol (shiitake reduced free cholesterol; maitake reduced total cholesterol).^[3] This is the study behind the claim that maitake lowers cholesterol in most competitor articles. It is an animal study from 1987. The human evidence for maitake's direct cholesterol-lowering effect has not matched the animal model data.

For readers specifically interested in maitake's blood pressure effects, where its evidence base is stronger, the article on Maitake D-Fraction and Blood Pressure Regulation covers that evidence in depth.

The Beta-Glucan Mechanism Both Share

Both shiitake and maitake contain beta-glucan polysaccharides, a shared mechanism for cardiovascular effects.

Beta-glucans lower cholesterol by binding bile acids in the intestine, reducing their reabsorption.^[6] When bile acid reabsorption decreases, the liver must synthesize more bile acids, and cholesterol is the substrate for this synthesis. The net effect is increased cholesterol clearance from the bloodstream.

Sima and colleagues (2018) reviewed the beta-glucan cholesterol mechanism across multiple sources.^[6] The effect size depends on beta-glucan solubility and dose. Oat beta-glucan has the strongest human evidence and is FDA-recognized for cholesterol claims. Mushroom beta-glucans have different structural characteristics: they tend toward beta-1,3/1,6-glucan branching patterns rather than the mixed-linkage beta-glucan in oats. Whether mushroom beta-glucans have equivalent bile acid binding to oat beta-glucan at equivalent doses is not established.

Both shiitake and maitake contribute beta-glucan to this mechanism. Shiitake has the additional eritadenine mechanism on top of this. The mechanistic superiority of shiitake for cholesterol outcomes has some biological basis.

Mechanism Map

Three Pathways, Two Mushrooms

Shiitake only

Eritadenine

1. 1Inhibits S-adenosyl-L-homocysteine (SAH) hydrolase
2. 2Shifts hepatic phospholipid metabolism
3. 3Promotes conversion of cholesterol to bile acids

Enman 2007 (10x strain variation); Yamada 2007 (SAHH inhibition); Spim 2021 RCT (triglycerides -10%, 66 days)

Shared

Beta-glucan

1. 1Binds bile acids in the intestine
2. 2Reduces bile acid reabsorption
3. 3Liver draws on cholesterol to synthesize new bile acids

Sima 2018 (β-glucans & cholesterol review). Present in both shiitake and maitake.

Maitake emphasis

Insulin & blood-pressure route

1. 1Improves insulin sensitivity
2. 2Lowers systolic blood pressure (renin-angiotensin modulation)
3. 3Direct serum-cholesterol effect is weaker in humans

Talpur 2002 (antihypertensive/insulin, rats); Kabir 1987 (BP + lipids, SHR)

Only shiitake carries the eritadenine (SAH-hydrolase) pathway. Both species share the beta-glucan bile-acid route, while maitake’s stronger human evidence sits in blood-pressure and insulin outcomes rather than direct serum-cholesterol lowering.

Side-by-Side: What the Evidence Actually Supports

Sources: Enman 2007, Yamada 2007, Spim 2021, Kabir 1987, Talpur 2002

The table makes the verdict clear: for cholesterol-specific outcomes in humans, shiitake has better evidence than maitake. Neither mushroom has the clinical trial depth of oyster mushroom, where a systematic review of clinical trials identified eight trials showing beneficial effects on cardiometabolic parameters.^[9]

For context on where oyster mushroom fits and the lovastatin mechanism specific to Pleurotus species, see Oyster Mushroom and LDL Cholesterol: Clinical Evidence and Mechanisms. For reishi's different evidence picture, see Reishi and Cholesterol Management: Triterpene Mechanisms. And for a cross-pillar cardiovascular comparison, Cordyceps and Vascular Health: Endothelial Function and Nitric Oxide covers a different cardiovascular pathway.

Safety — shiitake dermatitis

Moderate

Raw or undercooked shiitake can trigger flagellate dermatitis

Concern

In the Spim 2021 double-blind trial, dermatitis occurred in 10% of participants sensitive to the mushroom. Flagellate dermatitis — linear, scratch-like skin marks — is a documented reaction to lentinan, a shiitake polysaccharide, when shiitake is eaten raw, undercooked, or in large quantities.

What the research says

Cook shiitake thoroughly and keep intake to normal culinary amounts; heat denatures lentinan and the reaction is not typical of properly cooked shiitake. Eritadenine content, and therefore any cholesterol effect, also varies up to 10-fold by strain, so a supplement's actual eritadenine load is not guaranteed.

Particularly relevant for: People eating raw/undercooked shiitake or large amounts, and anyone using concentrated shiitake supplements for cholesterol

What to do

Consult a physician before using shiitake or maitake to manage cholesterol. This article is educational and is not medical advice.

Spim et al., 2021 (trial dermatitis finding); Enman et al., 2007 (strain variation)

The Bottom Line

Shiitake and maitake differ substantially in their cholesterol-relevant mechanisms and evidence bases. Shiitake contains eritadenine, a unique compound that inhibits SAH hydrolase and promotes cholesterol conversion to bile acids; eritadenine content varies 10-fold across strains. The only double-blind shiitake RCT (Spim 2021, 66 days) confirmed significant triglyceride reduction with a safety note about flagellate dermatitis. Maitake's primary cardiovascular strengths are blood pressure regulation and insulin sensitization rather than direct cholesterol lowering. Both mushrooms share a beta-glucan bile acid sequestration mechanism. For cholesterol outcomes specifically, shiitake has stronger direct human evidence than maitake; oyster mushroom has the strongest human clinical evidence among all mushroom species.

Frequently Asked Questions

Is shiitake or maitake better for cholesterol?

Shiitake has stronger direct evidence for cholesterol outcomes. It contains eritadenine, a unique compound that promotes cholesterol conversion to bile acids, and one double-blind RCT (Spim 2021, 66 days) confirmed significant triglyceride reduction. Maitake's primary cardiovascular benefits are blood pressure reduction and insulin sensitization rather than direct serum cholesterol lowering.

Does maitake mushroom lower cholesterol?

The human evidence for maitake's direct cholesterol-lowering effect is limited. Animal model studies (including Kabir 1987) showed maitake reduced cholesterol and blood pressure in rats, but human clinical trial data for cholesterol specifically is not well-established. Maitake's stronger cardiovascular evidence is for blood pressure regulation and metabolic health (insulin sensitization).

What is eritadenine and does it lower cholesterol?

Eritadenine is a bioactive compound found primarily in shiitake mushrooms. It inhibits S-adenosyl-L-homocysteine hydrolase, which through a metabolic cascade promotes conversion of cholesterol to bile acids in the liver. This mechanism is distinct from beta-glucan bile acid binding or HMG-CoA inhibition (statins). Selected shiitake strains contain up to 10 times more eritadenine than levels reported for other strains (Enman et al., 2007).

What is the best evidence for shiitake and cholesterol?

The best human evidence is a 66-day double-blind randomized clinical trial (Spim et al., 2021) that found significant triglyceride reduction in adults with borderline high cholesterol consuming shiitake bars. LDL-specific reductions were limited. Some participants developed flagellate dermatitis, an adverse effect associated with raw or undercooked shiitake in large amounts. Cooked shiitake at culinary quantities does not typically cause this reaction.

Which mushroom is better for cholesterol: shiitake or maitake?

Shiitake has stronger direct cholesterol evidence. It has one double-blind RCT confirming triglyceride reduction and a unique mechanism (eritadenine) not found in maitake. Maitake's cardiovascular evidence is more consistent for blood pressure and insulin sensitization. Both are weaker than oyster mushroom, which has a systematic review of clinical trials identifying eight trials with beneficial cardiometabolic effects (Dicks et al., 2020).

How does shiitake reduce cholesterol differently from other mushrooms?

Shiitake reduces cholesterol through eritadenine, a compound that inhibits SAH hydrolase and promotes cholesterol-to-bile-acid conversion. This is mechanistically distinct from oyster mushroom's lovastatin content (HMG-CoA inhibition) and from the beta-glucan bile acid sequestration mechanism shared by multiple species. Eritadenine gives shiitake a pathway to cholesterol reduction that no other commonly consumed mushroom replicates (Gil-Ramirez et al., 2018).

Sources & References

1. 1RTHM-01436·Spim, Sara Rosicler Vieira et al. (2021). “Effects of Shiitake Culinary-Medicinal Mushroom, Lentinus edodes (Agaricomycetes), Bars on Lipid and Antioxidant Profiles in Individuals with Borderline High Cholesterol: A Double-Blind Randomized Clinical Trial..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
2. 2RTHM-00211·Enman, Josefine et al. (2007). “Quantification of the bioactive compound eritadenine in selected strains of shiitake mushroom (Lentinus edodes)..” Journal of agricultural and food chemistry.Study breakdown →PubMed →↩
3. 3RTHM-00007·Kabir, Y et al. (1987). “Effect of shiitake (Lentinus edodes) and maitake (Grifola frondosa) mushrooms on blood pressure and plasma lipids of spontaneously hypertensive rats..” Journal of nutritional science and vitaminology.Study breakdown →PubMed →↩
4. 4RTHM-00053·Talpur, Nadeem A et al. (2002). “Antihypertensive and metabolic effects of whole Maitake mushroom powder and its fractions in two rat strains..” Molecular and cellular biochemistry.Study breakdown →PubMed →↩
5. 5RTHM-00294·Kundaković, Tatjana et al. (2013). “Therapeutic properties of mushrooms in managing adverse effects in the metabolic syndrome..” Current topics in medicinal chemistry.Study breakdown →PubMed →↩
6. 6RTHM-00531·Sima, Petr et al. (2018). “β-glucans and cholesterol (Review)..” International journal of molecular medicine.Study breakdown →PubMed →↩
7. 7RTHM-00510·Gil-Ramírez, Alicia et al. (2018). “Molecular actions of hypocholesterolaemic compounds from edible mushrooms..” Food & function.Study breakdown →PubMed →↩
8. 8RTHM-01810·Uffelman, Cassi N et al. (2023). “An Assessment of Mushroom Consumption on Cardiometabolic Disease Risk Factors and Morbidities in Humans: A Systematic Review..” Nutrients.Study breakdown →PubMed →↩
9. 9RTHM-00614·Dicks, Lisa et al. (2020). “Effect of the Intake of Oyster Mushrooms (Pleurotus ostreatus) on Cardiometabolic Parameters-A Systematic Review of Clinical Trials..” Nutrients.Study breakdown →PubMed →↩
10. 10RTHM-00238·Yamada, Taro et al. (2007). “Structure and function of eritadenine and its 3-deaza analogues: potent inhibitors of S-adenosylhomocysteine hydrolase and hypocholesterolemic agents..” Biochemical pharmacology.Study breakdown →PubMed →↩